|
gptkbp:instance_of
|
gptkb:skincare_product
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Genzyme
gptkb:Sanofi_Genzyme
gptkb:Genzyme_Corporation
|
|
gptkbp:activities
|
lubricates joint
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:1997
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Synvisc-One
|
|
gptkbp:clinical_trial
|
Phase IV
pain relief
Phase III
efficacy in knee osteoarthritis
|
|
gptkbp:contains
|
hyaluronic acid
|
|
gptkbp:contraindication
|
infection at injection site
severe allergies to avian proteins
|
|
gptkbp:dosage_form
|
single-use vials
multi-dose vials
3 injections over 3 weeks
|
|
gptkbp:duration
|
up to 6 months
|
|
gptkbp:education
|
informed consent required
monitor for side effects
activity modification recommended
post-injection care advised
|
|
gptkbp:feedback
|
varies by individual
|
|
gptkbp:formulation
|
viscous gel
|
|
gptkbp:frequency
|
once a week
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Synvisc
|
|
gptkbp:ingredients
|
hyaluronan
|
|
gptkbp:is_available_in
|
multiple countries
|
|
gptkbp:is_considered
|
active infections
bleeding disorders
severe joint damage
|
|
gptkbp:is_used_for
|
osteoarthritis
|
|
gptkbp:manager
|
intra-articular
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:marketed_as
|
gptkb:Sanofi
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
varies by location
|
|
gptkbp:products
|
gptkb:Euflexxa
gptkb:Hyalgan
gptkb:Orthovisc
gptkb:Supartz
|
|
gptkbp:provides_information_on
|
gptkb:American_Academy_of_Orthopaedic_Surgeons
|
|
gptkbp:research_focus
|
cost-effectiveness
patient satisfaction
long-term effects
safety profile
comparative effectiveness
|
|
gptkbp:side_effect
|
allergic reaction
pain at injection site
joint swelling
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:suitable_for
|
gptkb:Person
pregnant women
nursing mothers
|
|
gptkbp:treatment
|
increased mobility
reduced pain
improved joint function
|
|
gptkbp:type_of_insurance
|
may vary
|